Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis (VALUE)

AbbVie

Status: Completed

Conditions: Chronic Plaque Psoriasis

Study type: Observational

Funder types: Industry

Identifiers

NCT03982394

P19-377

Details and patient eligibility

About

This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.

Enrollment: 2,759 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a specialist and presence of moderate to severe psoriasis symptoms according to physician's judgement at time of recruitment.
• Participant starting any approved treatment for psoriasis and physician's decision must be reached prior to recruitment in the study.
• Participant willing to continue with study documentation after cessation of therapy.

Exclusion criteria

• Unwillingness or inability to comply with study requirements.
• Participation in an interventional clinical trial, concurrently or within the last 30 days. Participation in a post-market observational study (PMOS) or Registry is acceptable.

Trial design

2,759 participants in 2 patient groups

Participants treated with other approved biological therapies

Description:

Treatment decision independently made of study enrollment

Participants treated with Risankizumab

Description:

Treatment decision independently made of study enrollment